MX359300B - Derivados de ingenol sobre la reactivacion del virus latente de inmunodeficiencia humana. - Google Patents

Derivados de ingenol sobre la reactivacion del virus latente de inmunodeficiencia humana.

Info

Publication number
MX359300B
MX359300B MX2014010463A MX2014010463A MX359300B MX 359300 B MX359300 B MX 359300B MX 2014010463 A MX2014010463 A MX 2014010463A MX 2014010463 A MX2014010463 A MX 2014010463A MX 359300 B MX359300 B MX 359300B
Authority
MX
Mexico
Prior art keywords
ingenol derivatives
reactivation
latent hiv
derivatives
relates
Prior art date
Application number
MX2014010463A
Other languages
English (en)
Other versions
MX2014010463A (es
Inventor
Luiz Francisco Pianowski
Amilcar Tanuri
Original Assignee
Amazonia Fitomedicamentos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102012004739A external-priority patent/BR102012004739A2/pt
Priority claimed from BR102012006549A external-priority patent/BR102012006549A2/pt
Application filed by Amazonia Fitomedicamentos Ltda filed Critical Amazonia Fitomedicamentos Ltda
Publication of MX2014010463A publication Critical patent/MX2014010463A/es
Publication of MX359300B publication Critical patent/MX359300B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G8/00—Condensation polymers of aldehydes or ketones with phenols only
    • C08G8/28—Chemically modified polycondensates
    • C08G8/30—Chemically modified polycondensates by unsaturated compounds, e.g. terpenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona ampliamente con el uso de ciertos derivados de ingenol como reactivadores del virus de inmunodeficiencia humana de virus latente de inmunodeficiencia humana en depósitos virales; en otro aspecto, la presente invención se relaciona con una asociación que comprende tales derivados de ingenol y agentes anti-retrovirales sustancialmente activos contra virus que se replican activamente.
MX2014010463A 2012-03-02 2013-03-01 Derivados de ingenol sobre la reactivacion del virus latente de inmunodeficiencia humana. MX359300B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102012004739A BR102012004739A2 (pt) 2012-03-02 2012-03-02 uso de um ou mais derivados de ingenol, associação farmacêutica, composição farmacêutica, adjuvante, método de travamento e método para a reativação do vírus hiv latente
BR102012006549A BR102012006549A2 (pt) 2012-03-23 2012-03-23 uso de um ou mais derivados de ingenol, associação farmacêutica, composição farmacêutica, adjuvante, método de tratamento e método para a reativação do vírus hiv latente
PCT/BR2013/000063 WO2013126980A1 (pt) 2012-03-02 2013-03-01 Derivados de ingenol na reativação de vírus hiv latente

Publications (2)

Publication Number Publication Date
MX2014010463A MX2014010463A (es) 2014-10-13
MX359300B true MX359300B (es) 2018-09-21

Family

ID=49081479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010463A MX359300B (es) 2012-03-02 2013-03-01 Derivados de ingenol sobre la reactivacion del virus latente de inmunodeficiencia humana.

Country Status (14)

Country Link
US (1) US10105339B2 (es)
EP (1) EP2821105B1 (es)
JP (1) JP6280510B2 (es)
CN (1) CN104136081B (es)
AU (1) AU2013225633B2 (es)
CA (1) CA2864995C (es)
ES (1) ES2683726T3 (es)
HK (1) HK1203872A1 (es)
IL (1) IL234404A (es)
IN (1) IN2014MN01911A (es)
MX (1) MX359300B (es)
NZ (1) NZ628408A (es)
RU (1) RU2609512C2 (es)
WO (1) WO2013126980A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102012028120B8 (pt) * 2012-11-01 2022-08-02 Amazonia Fitomedicamentos Ltda Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
WO2016022358A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Compositions and methods for reactivating latent viral infections
CA2984991A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
WO2016191836A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-dodecanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação de 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2016191837A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-hexanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação do composto 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
CN105079323B (zh) * 2015-09-15 2019-08-23 北京工业大学 几种中药提取物在hiv潜伏再激活治疗中的应用
CN106928063B (zh) * 2015-12-31 2020-09-01 上海鑫昊生物科技有限公司 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用
WO2017130156A1 (en) 2016-01-27 2017-08-03 Glaxosmithkline Intellectual Property (No.2) Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
CN109912419A (zh) * 2017-12-13 2019-06-21 复旦大学 巨大戟烷型二萜及其在制备抗艾滋病毒药物中的用途
CN110251495B (zh) * 2018-03-12 2022-05-31 重庆医科大学 20-脱氧巨大戟二萜醇在制备抑制hbv复制的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07165600A (ja) * 1993-10-18 1995-06-27 Souyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
JP2003171349A (ja) * 2001-08-06 2003-06-20 Univ Nihon 新規なジテルペン類、及びこれを用いた組成物、抗炎症剤、抗癌剤
WO2006116897A1 (fr) * 2005-04-30 2006-11-09 Nihon University Diterpenes provenant de euphorbia kansui et leur utilisation
ES2428244T3 (es) * 2005-06-28 2013-11-06 Amaz�Nia Fitomedicamentos Ltda. Fracci�n activa de un extracto de disolvente polar del l�tex de plantas Euforbi�ceas
KR101485883B1 (ko) 2007-04-30 2015-01-27 레오 라보라토리즈 리미티드 바이러스 유도 병변의 치료
JP2013517262A (ja) * 2010-01-15 2013-05-16 アマゾニア・フイートメデイカメントス・リミタダ 抗エイズ剤としての多環式化合物の医薬的使用
WO2011086424A1 (en) 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds mixtures as concomitant anti-cancer, anti-inflammatory and anti-pain agents

Also Published As

Publication number Publication date
US20150030638A1 (en) 2015-01-29
IL234404A (en) 2017-09-28
IN2014MN01911A (es) 2015-07-10
US10105339B2 (en) 2018-10-23
HK1203872A1 (en) 2015-11-06
ES2683726T3 (es) 2018-09-27
EP2821105B1 (en) 2018-05-23
CA2864995A1 (en) 2013-09-06
AU2013225633B2 (en) 2017-11-23
AU2013225633A1 (en) 2014-08-28
MX2014010463A (es) 2014-10-13
EP2821105A4 (en) 2015-11-04
CA2864995C (en) 2016-12-06
CN104136081A (zh) 2014-11-05
NZ628408A (en) 2017-09-29
WO2013126980A1 (pt) 2013-09-06
RU2609512C2 (ru) 2017-02-02
JP2015508782A (ja) 2015-03-23
RU2014139825A (ru) 2016-04-20
EP2821105A8 (en) 2015-04-29
EP2821105A1 (en) 2015-01-07
CN104136081B (zh) 2018-05-15
JP6280510B2 (ja) 2018-02-14

Similar Documents

Publication Publication Date Title
MX359300B (es) Derivados de ingenol sobre la reactivacion del virus latente de inmunodeficiencia humana.
TWD163155S (zh) 耳機
IL238130B (en) Modified recombinant viruses containing the pr13.5 promoter and their uses
TWD161131S (zh) 保溫瓶
AU338648S (en) Packaging
TR201816986T4 (tr) Terapötik ajan iletim formülasyonlarına yönelik lipitler.
AU338647S (en) Packaging
CO6821908A2 (es) Prenda absorbente desechable que tiene superficies coloreadas y una pretina integral
MX2012008790A (es) Antigenos de tuberculosis modificados.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
TWD165721S (zh) 自動點唱機之部分（一）
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
EA201492289A1 (ru) Композиции, содержащие аптамер против pdgf и антагонист vegf
AU341275S (en) Flask
AU343911S (en) Animal garment
AU348863S (en) Divided party tray
TWD175860S (zh) 碳粉匣之部分
AU342436S (en) Teapot
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
TWD176133S (zh) 碳粉匣之部分
EA201490399A1 (ru) Иммунотерапия hcv (вируса гепатита c)
ES2543850R2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
GB2510524A (en) Pulmonary hypertension
AU345245S (en) Muffler
WO2014025749A3 (en) Small molecule inhibitors of viral protein interactions with human t-rna

Legal Events

Date Code Title Description
FG Grant or registration